CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
7.57
-0.25 (-3.20%)
At close: Apr 28, 2026, 4:00 PM EDT
7.60
+0.03 (0.40%)
After-hours: Apr 28, 2026, 7:47 PM EDT
CorMedix Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for CorMedix stock have an average target of 14.83, with a low estimate of 13 and a high estimate of 19. The average target predicts an increase of 95.90% from the current stock price of 7.57.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CorMedix stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $13 → $14 | Buy | Maintains | $13 → $14 | +84.94% | Apr 28, 2026 |
| Citizens | Citizens | Buy Reiterates $19 | Buy | Reiterates | $19 | +150.99% | Apr 28, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $13 → $14 | Buy | Maintains | $13 → $14 | +84.94% | Apr 28, 2026 |
| Needham | Needham | Strong Buy Maintains $14 → $15 | Strong Buy | Maintains | $14 → $15 | +98.15% | Apr 27, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +84.94% | Apr 27, 2026 |
Financial Forecast
Revenue This Year
312.65M
from 311.71M
Increased by 0.30%
Revenue Next Year
295.89M
from 312.65M
Decreased by -5.36%
EPS This Year
0.85
from 2.04
Decreased by -58.46%
EPS Next Year
0.69
from 0.85
Decreased by -18.88%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 329.2M | 337.0M | ||||||
| Avg | 312.7M | 295.9M | ||||||
| Low | 288.6M | 260.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 5.6% | 7.8% | ||||||
| Avg | 0.3% | -5.4% | ||||||
| Low | -7.4% | -16.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.32 | 1.16 | ||||||
| Avg | 0.85 | 0.69 | ||||||
| Low | 0.42 | 0.25 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -35.4% | 36.3% | ||||||
| Avg | -58.5% | -18.9% | ||||||
| Low | -79.3% | -71.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.